




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Hot Topic

COVID-19 Therapeutic and Prevention



ENGLISH VERSION

We are publishing a special issue dedicated to the coronavirus, in all its aspects of management and treatment. Indeed, in the 21st century, it is necessary to share data as quickly as possible, including the publication of preliminary data, so that in the time of care and management, the maximum should be done to help infected patients and decision-makers in strategies to fight this new virus [1]. This responds to recent recommendations and has the advantage over the pre-prints, which are currently available, of having been urgently reviewed by competent reviewers in the field, to assess their credibility. Thus, in order to meet modern needs for dissemination of data on emerging pathogens and disease, the combination of speed and credibility assessment becomes essential elements in the response against epidemics.

The response to the creation of a such special issue also takes into account the fact that not only the disease is emerging, but that it originates from “emerging countries”, and giving everyone access to preliminary data from the Far East is a necessity for patient management in other areas. In particular, we see that a controversy has arisen in the use of repositioning treatments, such as chloroquine [2,3], for coronavirus, which justifies calling on those who have the most experience with this disease to communicate to the rest of the scientific world, in order to shed light on the choices to come.

FRENCH VERSION

Nous éditons un numéro spécial consacré au coronavirus (COVID-19), dans tous ses aspects de prise en charge et de traitement. En effet, au 21^{ème} siècle, il est nécessaire de partager les données aussi rapidement que possible, y compris par la publication de données préliminaires, de façon à ce que dans le temps du soin et de la prise en charge, le maximum puisse être fait pour aider les patients infectés et les preneurs de décisions dans les stratégies de lutte contre ce nouveau virus. Ceci répond à des recommandations récentes et présente l'avantage sur les pré-print, qui sont actuellement disponibles, d'avoir été reviewés en urgence par des reviewers compétents du domaine, afin d'en évaluer la crédibilité. Ainsi, pour répondre aux besoins modernes de diffusion des données sur les pathogènes émergents, l'association de la vitesse et de l'évaluation de la crédibilité deviennent des éléments essentiels dans la réponse contre les épidémies.

La réalisation d'un tel numero spécial tient compte du fait que non seulement la maladie est émergente, mais qu'elle est issue de

pays émergents, pour pouvoir donner à tous l'accès aux données préliminaires d'Extrême Orient ce qui est une nécessité pour prendre en charge les malades dans d'autres pays du Monde. En particulier, on voit qu'une polémique est apparue au sujet de l'usage et du repositionnement de médicaments existants comme la Chloroquine ce qui justifie l'appel à ceux qui ont le plus d'expérience dans le traitement de cette maladie afin d'éclairer sur les choix thérapeutiques à venir.

CHINESE VERSION (Traditional Chinese)

我們正在籌備發表有關冠狀病毒的特輯，其中包含處置和治療的各個方面。在21世紀，能盡快分享數據是必要的，即便是初步數據，也是有助於在照護期間，能盡到最大努力去幫助感染者和決策者制定策略去對抗這種新病毒 [1]。為了能對最新建議做出及時有效的反應，這系列的文章會由相關領域的合格審閱者做迅速地評估其可信度，因此與現有的預印本相較，具有較高的公信力。為了能滿足現代傳播病原體和相關疾病知識的需求，同時合併效率和可信度評估的知識傳播已成為因應傳染病大流行的必需。

對於籌備這樣一個特輯要考慮到不僅疾病本身正在持續出現，而且這一疾病來自“新興國家 (emerging countries)”，需要讓每個人都可以從獲得來自遠東地區的初步數據得以藉此經驗去處置其他地區的病人。尤其是，我們看到了在針對冠狀病毒使用類似抗瘧疾藥-磷酸氯喹 (Chloroquine Phosphate) 治療的爭議 [2, 3]，這適足以呼籲對這種疾病有最豐富經驗的人們能與其他科學家交流來讓大家進一步釐清真相。

CHINESE VERSION (Simplified Chinese)

我们正在筹备发表有关冠状病毒的特辑，其中包含处置和治疗的各个方面。在21世纪，能尽快分享数据是必要的，即便是初步数据，也是有助于在照护期间，能尽到最大努力去帮助感染者和决策者制定策略去对抗这种新病毒 [1]。为了能对最新建议做出及时有效的反应，这系列的文章会由相关领域的合格审阅者做迅速地评估其可信度，因此与现有的预印本相较，具有较高的公信力。为了能满足现代传播病原体和相关疾病知识的需求，同时合并效率和可信度评估的知识传播已成为因应传染病大流行的必需。

对于筹备这样一个特辑要考虑到不仅疾病本身正在持续出现，而且这一疾病来自“新兴国家 (emerging countries)”，需要让每个人都可以从获得来自远东地区的初步数据得以藉此经验去处置其他地区的病人。尤其是，我们看到了在针对冠状病毒使用类似抗疟疾药-磷酸氯喹 (Chloroquine Phosphate) 治疗的争议 [2, 3]，这适足以呼吁对这种疾病有最丰富经验的人们能与其他科学家交流来让大家进一步厘清真相。

ITALIAN VERSION

International Journal of Antimicrobial Agents intende pubblicare un numero speciale dedicato al coronavirus, prendendo in considerazione lavori che includano ogni suo aspetto, dalla gestione al trattamento. In questo secolo è sempre più importante condividere i dati il più rapidamente possibile, includendo nelle pubblicazioni anche risultati preliminari, che possano in qualche modo essere d'aiuto nel trattamento e nella gestione di questi pazienti, affiancandosi quindi e aiutando i responsabili delle decisioni strategiche da attuare per combattere questo nuovo virus [1]. Tutto questo risponde alle recenti raccomandazioni riguardanti la disseminazione rapida dei risultati e presenta il vantaggio - rispetto alle bozze di stampa attualmente disponibili, - di venire prontamente valutate da revisori competenti nel settore, per valutare la loro credibilità. Pertanto, al fine di soddisfare le moderne esigenze di diffusione dei dati sui patogeni e le malattie emergenti, la combinazione di valutazione della velocità e della credibilità diventa un elemento essenziale nella risposta contro le epidemie.

L'idea della pubblicazione di questo numero speciale tiene conto del fatto che non solo sta emergendo una nuova malattia, ma che questa proviene dai "paesi emergenti" facendo diventare importantissimo l'accesso ai dati preliminari dall'Estremo Oriente, in modo da far condividere la loro esperienza di gestione ai colleghi di altre aree del pianeta. In particolare, stiamo assistendo ad una controversia nell'uso e nel riposizionamento di alcuni trattamenti, un esempio è la cloroquina [2,3], per le infezioni sostenute da coronavirus, giustificando quindi il nostro appello verso coloro che hanno acquisito esperienze con questa malattia al fine di comunicare questa loro conoscenza al resto del mondo. Tutto questo aiuterà a far luce sulle scelte in divenire.

Didier Raoult*

*MEΦI, IRD, Aix Marseille Univ, AP-HM, Marseille, France
IHU-Méditerranée Infection, Marseille, France*

Po-Ren Hsueh

Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

Stefania Stefani¹

University of Catania, Department of Biomedical and Biotechnological Sciences, Biological Tower, Third floor -Est Tower, Catania, Italy

Jean-Marc Rolain²

*MEΦI, IRD, Aix Marseille Univ, AP-HM, Marseille, France
IHU-Méditerranée Infection, Marseille, France*

*Corresponding author: Tel: 04 13 73 24 01.

E-mail address: didier.raoult@gmail.com (D. Raoult)

¹ Editor in Chief of Journal of Global Antimicrobial Resistance (<https://www.journals.elsevier.com/journal-of-global-antimicrobial-resistance>). The International Society of Antimicrobial Chemotherapy (<https://www.isac.world/>).

² Editor in Chief of International Journal of Antimicrobial Agents (<https://www.journals.elsevier.com/international-journal-of-antimicrobial-agents>). The International Society of Antimicrobial Chemotherapy (<https://www.isac.world/>)

References

- [1] Anonymous Coronavirus: keep sharing research. *Nature* 2020;578(7793):7.
- [2] Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. *Int J Antimicrob Agents* 2020 Feb 15:105923.
- [3] Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. *Int J Antimicrob Agents* 2020 press.